依布替尼抑制间充质干细胞介导的弥漫大B细胞淋巴瘤耐药
研究以弥漫大B细胞淋巴瘤(DLBCL)细胞系及原代细胞与骨髓间充质干细胞(MSC)共培养,并用NOD/SCID小鼠模型观察依布替尼的作用。结果显示依布替尼靶向CXCL12/CXCR4轴,降低CXCL12分泌和CXCR4表达,抑制MSC介导的耐药,并减少集落形成和肿瘤生长。
要点
- 依布替尼剂量依赖性抑制DLBCL细胞向MSC迁移和黏附(P<0.05)。
- 依布替尼降低MSC分泌CXCL12及DLBCL细胞CXCR4表达(P<0.05)。
- 依布替尼联合米托蒽醌在MSC共培养时提高HBL-1细胞凋亡比例。
核心结论
- 依布替尼靶向CXCL12/CXCR4轴,抑制CXCR4表达从而克服MSC介导的耐药,并在体内外抑制MSC促淋巴瘤细胞集落形成。
研究设计与样本
- 体外实验以DLBCL细胞系SUDHL10(GCB亚型)、HBL-1(ABC亚型)及8例DLBCL患者原代细胞为研究对象,与正常人骨髓基质细胞(MSC)共培养。
- 体内实验以HBL-1细胞构建的NOD/SCID肿瘤模型小鼠为研究对象,观察依布替尼治疗后肿瘤体积变化。
- 采用ELISA法检测MSC的CXCL12表达水平,流式细胞术检测DLBCL细胞的CXCR4表达水平及细胞凋亡水平。
- 以携带有CXCR4的慢病毒转染HBL-1细胞,米托蒽醌、依布替尼处理后与MSC共培养,流式细胞术检测细胞凋亡水平。
- 倒置显微镜下观察HBL-1细胞集落形成情况,每3天通过卡尺测量评估肿瘤生长。
主要发现
- 依布替尼处理后DLBCL细胞向MSC的迁移数和与MSC的黏附比例明显降低(P值均<0.05),并呈剂量依赖性。
- 与依布替尼处理前比较,处理后MSC的CXCL12表达水平降低:SUDHL10细胞660 pg/ml对1 400 pg/ml,P=0.004;HBL-1细胞720 pg/ml对1 490 pg/ml,P=0.018;DLBCL原代细胞850 pg/ml对1 450 pg/ml,P=0.004。
- 依布替尼处理后DLBCL细胞的CXCR4表达水平降低(P值均<0.05)。
- 共培养时,对照组、米托蒽醌组、依布替尼组、米托蒽醌组+依布替尼组的HBL-1细胞凋亡比例分别为15.1%、17.5%、23.5%、58.7%。
- 转染过表达CXCR4后,HBL-1细胞凋亡比例分别为14.2%、16.1%、22.5%、38.3%;共培养联合用药组HBL-1细胞凋亡比例高于单药培养组,差异均有统计学意义(P值均<0.05)。
关键数值与推荐
- 依布替尼抑制MSC分泌CXCL12:SUDHL10细胞660 pg/ml对1 400 pg/ml(P=0.004),HBL-1细胞720 pg/ml对1 490 pg/ml(P=0.018),DLBCL原代细胞850 pg/ml对1 450 pg/ml(P=0.004)。
- 共培养时HBL-1细胞凋亡比例:对照组15.1%、米托蒽醌组17.5%、依布替尼组23.5%、米托蒽醌+依布替尼组58.7%。
- 转染过表达CXCR4后HBL-1细胞凋亡比例:对照组14.2%、米托蒽醌组16.1%、依布替尼组22.5%、米托蒽醌+依布替尼组38.3%。
- 集落数:对照组113±5、MSC组205±4、依布替尼组62±9、MSC+依布替尼组123±3(每孔2.5×10^3,x±s)。
- 模型小鼠皮下肿瘤体积:对照组6 500 mm^3、MSC组17 000 mm^3、依布替尼组4 000 mm^3、MSC+依布替尼组10 000 mm^3。
临床怎么用
- 原文结论为依布替尼靶向CXCL12/CXCR4轴、抑制CXCR4表达从而克服MSC介导的耐药,为依布替尼治疗复发耐药DLBCL提供了理论依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the mechanism of ibrutinib on drug resistance diffuse large B-cell lymphoma (DLBCL) cells. Methods: DLBCL cell line was cultured with mesenchymal stem cells (MSC) , and DLBCL cells which migrated and adhered to MSC under microscope was counted. The secretion of CXCL12 by MSC were measured by ELISA. The expression of CXCR4 on DLBCL cells were measured by flow cytometry, HBL-1 cells were transfected with a CXCR4-lentivector. An Annexin Ⅴ-binding assay was used to detect the induction of apoptosis. Clonogenic growth of DLBCL cells was evaluated on MethoCult media. Ibrutinib was injected into NOD/SCID mice, tumor growth was assessed via caliper measurements every 3 days. Results: MSC promoted migration and adhesion of DLBCL cells to MSC. Ibrutinib inhibited migration and adhesion of DLBCL cells to MSC in a dose-dependent manner (P<0.05) . CXCL12 secreted by MSC and CXCR4 expressed on DLBCL cells could induce each other, which upgraded the levels of secretion and expression. Ibrutinib could inhibit the secretion of CXCL12 (SUDHL10: 660 pg/ml vs 1 400 pg/ml, P=0.004; HBL-1: 720 pg/ml vs 1 490 pg/ml, P=0.018; DLBCL:850 pg/ml vs 1 450 pg/ml, P=0.004) and expression of CXCR4 (P<0.05) . When co-cultured with MSC, the ratio of HBL-1 cells apoptosis in the group of control, mitoxantrone, ibrutinib, mitoxantrone+ibrutinib were respectively 15.1%, 17.5%, 23.5%, 58.7%. After transfected with a CXCR4-lentivector and overexpressed CXCR4, the ratios of HBL-1 cells apoptosis were 14.2%, 16.1%, 22.5%, 38.3% respectively. The ratio of DLBCL cells apoptosis induced by mitoxantrone was lower when co-cultured with MSC (P<0.05) . But with the addition of ibrutinib, the ratio of apoptosis was increaed and it was similar to cultivation without MSC, which suggested ibrutinib could inhibit drug-resistance induced by MSC. But after transfected with a CXCR4-lentivector, the overexpression of CXCR4 was detected and the ratio of apoptosis was significantly lower when co-cultured with MSC which demonstrated that ibrutinib inhibited drug-resistance by inhibiting the expression of CXCR4. MSC enhanced lymphoma clonogenicity in vitro and lymphoma cell growth in vivo. The number of colonies of control, MSC, Ibrutinib, MSC+Ibrutinib were 113±5, 205±4, 62±9, 123±3 (2.5×10(3)/well, x±s) , respectively. The tumor volume of NOD/SCID mice were respectively 6 500, 17 000, 4 000, 10 000 mm(3). Ibrutinib inhibited lymphoma clonogenicity in vitro and lymphoma cell growth in vitro. Conclusion: Ibrutinib targeted the CXCL12/CXCR4 axis, inhibited the expression of CXCR4 and inhibited MSC-mediated drug resistance. Ibrutinib also inhibited lymphoma clonogenicity in vitro and lymphoma cell growth in vivo. These results provided a scientific rationality for relapsed/refractory DLBCL treatment with ibrutinib. 目的: 探讨依布替尼克服弥漫大B细胞淋巴瘤(DLBCL)细胞耐药的机制。 方法: ①体外实验:以DLBCL细胞系SUDHL10细胞(GCB亚型)、HBL-1(ABC亚型)以及8例DLBCL患者原代细胞为研究对象,与正常人骨髓基质细胞(MSC)共培养后,显微镜下计数向MSC趋化迁移及与MSC黏附的DLBCL细胞数,ELISA法检测MSC的CXCL12表达水平,流式细胞术检测DLBCL细胞的CXCR4表达水平;以携带有CXCR4的慢病毒转染HBL-1细胞,米托蒽醌、依布替尼处理后与MSC共培养,流式细胞术检测细胞凋亡水平;倒置显微镜下观察HBL-1细胞集落形成情况。②体内实验:以HBL-1细胞构建的NOD/SCID肿瘤模型小鼠为研究对象,观察依布替尼治疗后肿瘤体积变化。 结果: ①依布替尼处理后,DLBCL细胞向MSC的迁移数和与MSC的黏附比例明显降低(P值均<0.05),并呈剂量依赖性。②与依布替尼处理前比较,处理后MSC的CXCL12表达水平降低(SUDHL10细胞:660 pg/ml对1 400 pg/ml,P=0.004;HBL-1细胞:720 pg/ml对1 490 pg/ml,P=0.018;DLBCL原代细胞:850 pg/ml对1 450 pg/ml,P=0.004),DLBCL细胞的CXCR4表达水平降低(P值均<0.05)。③共培养时,对照组、米托蒽醌组、依布替尼组、米托蒽醌组+依布替尼组的HBL-1细胞凋亡比例分别为15.1%、17.5%、23.5%、58.7%,转染过表达CXCR4后,HBL-1细胞凋亡比例分别为14.2%、16.1%、22.5%、38.3%,共培养联合用药组HBL-1细胞凋亡比例高于单药培养组,差异均有统计学意义(P值均<0.05)。④对照组、MSC组、依布替尼组、MSC组+依布替尼组集落数分别为113±5、205±4、62±9、123±3(每孔2.5×10(3)),模型小鼠皮下肿瘤体积分别为6 500、17 000、4 000、10 000 mm(3),依布替尼处理后较处理前集落数和肿瘤体积明显减少,差异均有统计学意义(P值均<0.05)。 结论: 依布替尼靶向作用于CXCL12/CXCR4轴,抑制CXCR4表达从而克服MSC介导的耐药作用,并且能够在体内外抑制MSC促淋巴瘤细胞集落形成的作用。为依布替尼治疗复发耐药DLBCL提供了理论依据。.
引用
- Wu L, Zhang YZ, Xia B, et al. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29365396. doi:10.3760/cma.j.issn.0253-2727.2017.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。